| Autor: |
López-Ruiz P; Department of Biochemistry and Molecular Biology, University of Alcalá, Alcalá de Henares, Madrid, Spain., Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colás B |
| Jazyk: |
angličtina |
| Zdroj: |
Anti-cancer agents in medicinal chemistry [Anticancer Agents Med Chem] 2011 Jan; Vol. 11 (1), pp. 89-98. |
| DOI: |
10.2174/187152011794941154 |
| Abstrakt: |
The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
